🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Dr. Joseph Mikhael, International Myeloma Foundation Chief Medical Officer, shares a brief overview of fatigue related to multiple myeloma in one minute. #AsktheIMF

Does IMF Chief Medical Officer Dr. Joseph Mikhael encourage clinical trials at each stage of treatment? Short answer: YES! Find the right clinical trial for you at myeloma.org/sparkcures/ and hashtag #AsktheIMF on social media to ask your own questions.

Dr. Joseph Mikhael, Chief Medical Officer of the IMF, explains how support groups can greatly improve outcomes in multiple myeloma. Not in a support group yet? Find a group near you at support.myeloma.org #AsktheIMF

Are kidney transplants more likely to result in myeloma coming back faster or more aggressively? IMF Chief Medical Officer Joseph Mikhael shares his take on the subject. Watch the full Q&A now: myeloma.org/node/11711 #AsktheIMF

Why do some people develop myeloma while others don’t? In this 60-second video, Dr. Joseph Mikhael, International Myeloma Foundation Chief Medical Officer, breaks down the top risk factors for multiple myeloma—including race, obesity, & environmental exposures like Agent Orange.

So richly deserved. Congrats!

Bispecific antibodies have revolutionized treatment for relapsed/refractory multiple myeloma, but they require special coordination between your infusion center, community oncologist—and you, the patient. myeloma.org/node/11738 Joseph Mikhael

2/2 Joseph Mikhael marivi mateos Beth Faiman PhD

We at the International Myeloma Foundation are always here for you. Call us at the InfoLine myeloma.org/infoline or visit myeloma.org to ask our myeloma chatbot Myelo your questions day & night. Watch the full video with Dr. Joe Joseph Mikhael myeloma.org/node/11738

Join us at our #NYC #IMFMPOWER Juneteenth event on 6/21! M-POWER yourself—learn about heritage, health, & hope regarding Black patients and families just getting started on their myeloma journey. Register before spots fill up: mmsm.link/45uIzzX #mmsm Joseph Mikhael Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰

Have you considered bispecific antibodies for your myeloma treatment? In this video, IMF Chief Medical Officer Joseph Mikhael breaks down how bispecifics can be used to treat myeloma. This episode of #MyelomaMadeSimple supported by Pfizer Inc.; watch now: myeloma.org/node/11738

📣 Meet the Co-Chairs for Great Debates in Hematologic Malignancies! Drs. Jessica K. Altman, John Leonard, Joseph Mikhael are shaping a dynamic program that will tackle evolving standards and real-world decision-making in hematologic malignancies. This conference isn’t just

Joseph Mikhael #ASCO25 #myeloma the master asking important questions about modifying dosing to help patients maintain excellent response while maintaining outstanding quality of life

See you on June 17 at our free #IMFIMWG Conference Series webinar! Hear from a panel of myeloma specialists on frontline therapy, MGUS, the evolution of CAR T-cell therapy, and more! Register now to save your seat: mmsm.link/4jlw25n Joseph Mikhael marivi mateos Beth Faiman PhD

Join us virtually on 7/1 to hear the top myeloma research presented at #ASCO25, #EHA25, & #IMFIMWG! IMF CMO Joseph Mikhael will highlight & explain meeting abstracts in approachable terms that patients can use in everyday care. mmsm.link/4kTQD1P #IMFASCO #IMFEHA

🧬 Understand how prognosis evolves through relapse cycles in MM. Gain confidence in SDM, 💊personalize treatment, and 🤝 improve communication in R/R MM care. 🔗 ms.spr.ly/6013S5Pf1 Moderated by: Joseph Mikhael

Don't miss our #IMFIMWG Conference Series webinar on June 17, 2025! Tune in virtually to hear from a panel of myeloma experts on the latest drug therapy news, SMM, MRD testing, and more. Register before it's too late: mmsm.link/4jlw25n Joseph Mikhael marivi mateos Beth Faiman PhD

Is CAR T-cell therapy better than a stem cell transplant? Dr. Joseph Mikhael, IMF Chief Medical Officer, tackles this complex question in this short clip. Watch the full video for more insight from the myeloma expert at myeloma.org/node/11744

🧬 Understand how prognosis evolves through relapse cycles in MM. Gain confidence in SDM, 💊personalize treatment, and 🤝 improve communication in R/R MM care. 🔗 ms.spr.ly/6012S5P4u Moderated by: Joseph Mikhael

Can any myeloma treatments make patients ineligible to receive CAR T-cell therapy? Joseph Mikhael, Chief Medical Officer of the IMF, explains in this short clip. Watch the full video with Dr. Joe at myeloma.org/node/11744